Prime Medicine, Inc.

PRME · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders23.7%

Institutions71.1%

Public / Other

	You	Peer avg
P/E	–	5.4
Revenue Growth	+3.5%	+32.6%
ROE	-373.3%	-35.3%

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$4.63M	$2.98M	–	$0
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$208.35M	-$202.47M	-$204.79M	-$116.54M
Operating income as a percentage of revenue.	-4498.1%	-6787.4%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$201.14M	-$195.88M	-$198.13M	-$121.82M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.35	$-1.65	$-2.18	$-4.19
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.35	$-1.65	$-2.18	$-4.19

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$63.03M	$182.48M	$41.57M	$187.62M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$342.73M	$297.51M	$193.85M	$360.31M
Everything the company owes — debt, unpaid bills, and other obligations.	$221.87M	$144.36M	$60.78M	$44.04M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$120.87M	$153.15M	$133.07M	$316.27M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$162.56M	-$122.86M	-$165.41M	-$131.83M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$4.53M	$7.29M	$8.72M	$16.09M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$167.09M	-$130.16M	-$174.14M	-$147.92M

Prime Medicine, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Peer Comparison

Income Statement

Balance Sheet

Cash Flow Statement